| A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia |
Ongoing |
VX 880 |
3 |
VX20-880-101 |
King Abdulaziz Hospital NG (Riyadh) , King Faisal Specialist Hospital and Research Center (Riyadh) |
| Patient and prescriber survey: effectiveness measures to investigate awareness, knowledge, and adherence to the additional risk minimisation measures (aRMM) of the patient reminder card for oral ambrisentan (PrVolibris®) |
Ongoing |
Ambrisentan |
4 |
221772 |
King Abdullah International Medical Research Center– Jeddah |
| A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure |
Ongoing |
Baxdrostat |
3 |
D6972C00002 |
King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Riyadh) |
| A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa |
Ongoing |
Lutikizumab |
3 |
M20-465 |
King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah) |
| Real-world evidence Non-Interventional proSpective study of kisqaLi (Ribociclib) Effectiveness and safety in patients with HR+/HER2- early Breast Cancer in Saudi Arabia |
Ongoing |
kisqaLi (ribociclib) |
2 |
CLEE011ASA |
King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Jeddah) |
| Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c 2.4 mg Once-weekly |
Ongoing |
Semaglutide |
3 |
NN9536-7752 |
King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) ,King Abdulaziz Hospital NG (Al Ahsa), King Abdulaziz Medical City NG (Jeddah) ,King Faisal Specialist Hospital and Research Center (Riyadh) , King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II (RAPIDe-2) |
Ongoing |
Deucrictibant |
2/3 |
PHA022121-C303 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Global, Phase 1/2, Open-label, Dose Optimization Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of mRNA-3927 in Participants with Propionic Acidemia |
Ongoing |
mRNA-3927 |
1/2 |
mRNA-3927-P101 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| Real-World Evidence non-interventional prospective study for the effectiveness, tolerability and adherence of Asciminib after two previous TKIs in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) in Saudi Arabia. (ASC4REAL) |
Ongoing |
Scemblix (Asciminib/ ABL001) |
4 |
CABL001ASA |
King Abdulaziz Medical City NG (Riyadh),King Abdulaziz Medical City NG (Jeddah),King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON) |
Ongoing |
BI 1015550 |
3 |
1305-0031 |
King Abdulaziz Medical City NG (Riyadh) |
